Today: 21 May 2026
Browse Category

NASDAQ:TMDX 13 January 2026 - 6 May 2026

TransMedics Group Stock Tumbles 23% as Profit Hit Overshadows Organ-Transplant Growth

TransMedics Group Stock Tumbles 23% as Profit Hit Overshadows Organ-Transplant Growth

TransMedics shares dropped 23% to $72.88 after first-quarter adjusted earnings of 30 cents per share missed estimates and profit fell to $7.3 million from $25.7 million. Revenue rose 21% to $173.9 million but missed forecasts, while gross margin slipped to 58% from 61% as operating expenses jumped. The company maintained its 2026 revenue outlook of $727–$757 million.
6 May 2026
··
TransMedics (TMDX) stock jumps 7% premarket after earnings, 2026 revenue outlook

TransMedics (TMDX) stock jumps 7% premarket after earnings, 2026 revenue outlook

TransMedics Group shares jumped 7.3% premarket to $147.88 after posting Q4 revenue of $160.8 million, up 32%, and setting a 2026 revenue forecast of $727–$757 million. Net income for the quarter reached $105.4 million, boosted by an $83.8 million tax benefit. Adjusted earnings were 57 cents per share, topping analyst estimates. Gross margin slipped to 58% as clinical service and freight costs rose.
25 February 2026
··
TransMedics stock jumps as SEC filing details $23.9 million-a-year lease for new Massachusetts HQ

TransMedics stock jumps as SEC filing details $23.9 million-a-year lease for new Massachusetts HQ

TransMedics shares rose about 8% Tuesday after the company disclosed a lease for nearly 498,000 square feet in Somerville, Massachusetts, to serve as its new global headquarters. The lease begins in early 2028 with base rent starting at $23.9 million per year and an $18 million security deposit. The stock touched $151.70 before closing at $145.68. State and local incentives could total up to $18 million if hiring targets are met.
13 January 2026
·

Stock Market Today

  • Thales (ENXTPA:HO) Shares Decline but DCF Model Indicates Undervaluation
    May 21, 2026, 1:56 AM EDT. Shares of Thales (ENXTPA:HO) have fallen 12.8% over the past month and are down 9.7% year on year, despite strong long-term returns of 79.2% and 203.0% over three and five years respectively. Recent sector-specific developments in aerospace and defense, alongside broader market sentiment, contribute to price volatility. A discounted cash flow (DCF) analysis estimates Thales's intrinsic value at around €306.76 per share, suggesting the current price of €229.50 trades at a 25.2% discount and that the stock is undervalued. The P/E ratio remains a key metric but further valuation aspects need evaluation, as Thales scores 4 out of 6 on Simply Wall St's valuation checks. Investors should consider these factors when assessing the stock's potential.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop